belatacept: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
belatacept: clinical details
Prescribing considerations
- Restrict prescribing and supervision to clinicians experienced in kidney transplantation and immunosuppression.
- Confirm positive EBV serology before treatment and assess for latent tuberculosis.
- Consider immunological risk and overall immunosuppressive burden, particularly in highly sensitised recipients.
- Record the product name and batch number for biological traceability.
- Avoid live vaccines and counsel on sun protection.
- Liver-transplant use is not recommended; paediatric safety and efficacy are not established.
Contraindications and cautions
- EBV-seronegative transplant recipients or those whose EBV status is unknown
- Hypersensitivity to belatacept or an excipient
Monitoring
- Assess graft function and evidence of acute rejection, especially following conversion.
- Monitor for serious and opportunistic infections, including CMV, BK virus, tuberculosis and PML.
- Remain alert to PTLD, other malignancies and suspicious skin lesions.
- Observe for infusion-related hypersensitivity or anaphylaxis.
- Therapeutic belatacept concentration monitoring is not required.
Clinical pharmacology
Belatacept is a recombinant CTLA-4–IgG1 fusion protein that selectively blocks CD80/CD86-mediated T-cell costimulation. It is not expected to undergo CYP or UGT metabolism.
Formulation and product differences
- Single-use powder for concentrate for intravenous infusion.
- Requires aseptic reconstitution and dilution using the supplied non-siliconised syringe to minimise aggregate formation.
- The prepared infusion requires a low-protein-binding inline filter and must not share an intravenous line with other agents.
- Contains sodium; consider this for patients following a controlled-sodium diet.
belatacept preparations and strengths
Solution for infusion
Route: Intravenous
Strengths: 250 mg
belatacept interactions
Belatacept has few expected metabolic interactions, but clinically important immune-system interactions remain.
Live vaccines
Avoid during treatment because immunosuppression may cause an unsafe response; other vaccines may also be less effective.
Mycophenolate mofetil or mycophenolic acid
Mycophenolic-acid exposure may be higher with belatacept than with ciclosporin, so adverse effects and overall immunosuppression require specialist review.
Other immunosuppressants, including lymphocyte-depleting therapies
Combined immunosuppression increases the risk of serious infection and malignancy. Treatment must be coordinated by the transplant team.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.